Quarterly report pursuant to Section 13 or 15(d)

Stock Plans

v3.19.2
Stock Plans
6 Months Ended
Jun. 30, 2019
Stock Plans  
Stock Plans

2.    Stock Plans

In January 2019, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 583,334 to 1,666,667.

In January 2019, our stockholders approved a repricing of 122,115 fully-vested stock options with exercise prices in excess of $21.00 held by employees and consultants other than the named executive officers or members of the Board. The effected options were repriced at $1.55. As a result of the repricing of these stock options, we incurred a total of approximately $136,000 of additional stock-based compensation expense during the six months ended June 30, 2019, of which approximately $77,000 was recorded within research and development and approximately $59,000 within selling, general and administrative in our condensed statement of operations and comprehensive loss.

The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30, 

 

June 30, 

 

    

2019

    

2018

    

2019

    

2018

Research and development

 

$

14

 

$

156

 

$

91

 

$

318

Selling, general and administrative

 

 

336

 

 

246

 

 

395

 

 

516

Total stock-based compensation

 

$

350

 

$

402

 

$

486

 

$

834

 

We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the fair value of our stock options:

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30, 

 

June 30, 

 

 

    

2019

    

2018

    

2019

    

2018

 

Weighted-average risk-free interest rate

 

2.1

%  

2.9

%  

2.2

%  

2.7

%

Expected dividend payments

 

 —

 

 —

 

 —

 

 —

 

Expected holding period (years) 1

 

 5.9

 

 6.4

 

 5.4

 

 6.4

 

Weighted-average volatility factor 2

 

0.93

 

0.91

 

0.94

 

0.89

 

Estimated forfeiture rates for options granted 3

 

21

%  

25

%  

21

%  

26

%

 

(1)

Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.

(2)

Weighted average volatility is based on the historical volatility of our common stock.

(3)

Estimated forfeiture rates are based on historical data.

The following table summarizes option activity:

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

Weighted

    

 

 

 

 

 

 

Weighted

 

Average

 

 

 

 

 

 

 

Average 

 

Remaining

 

Aggregate

 

 

 

 

Exercise

 

Option

 

Intrinsic

 

 

Options (in

 

Price per

 

Term (in

 

Value (in

 

 

thousands)

 

share

 

years)

 

thousands)

Outstanding at January 1, 2019

 

665

 

$

17.94

 

 6.44

 

$

4.0

Granted

 

854

 

 

1.64

 

 

 

 

 

Cancelled

 

(217)

 

 

26.49

 

 

 

 

 

Outstanding at June 30, 2019

 

1,302

 

 

5.82

 

8.47

 

 

0.8

Exercisable at June 30, 2019

 

669

 

 

9.83

 

7.23

 

 

0.1

 

As of June 30, 2019, there was approximately $0.7 million of total unrecognized compensation expense related to non-vested stock options. This expense was expected to be recognized over a weighted-average period of approximately 1.75 years.